Home » CRUCELL TO LICENSE PER.C6 CELL LINE TECHNOLOGY TO VAKZINE PROJEKT MANAGEMENT
CRUCELL TO LICENSE PER.C6 CELL LINE TECHNOLOGY TO VAKZINE PROJEKT MANAGEMENT
Crucell NV said it has agreed to license its PER.C6 human cell-line technology to German vaccine development company Vakzine Projekt Management (VPM) GmbH for use in the development of a vaccine to prevent a specific but undisclosed infectious disease, and to develop diagnostics. Under the terms of the agreement, Crucell will receive a research license fee and annual maintenance fees. Further financial details were not disclosed.
Forbes (http://www.forbes.com/business/feeds/afx/2005/12/08/afx2377310.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May